INCIDENCE AND RISK FACTORS OF FEBRILE NEUTROPENIA IN PATIENTS WITH NON HODGKIN S LYMPHOMA: A NARRATIVE REVIEW

In individuals with non-Hodgkin's lymphoma (NHL), febrile neutropenia is a severe and potentially fatal side effect of chemotherapy. It is linked to longer hospital stays, higher rates of morbidity and mortality, and disruptions in cancer therapy. The intensity of chemotherapy regimens, disease-related factors, and patient characteristics all affect the incidence of febrile neutropenia. The purpose of this narrative review is to provide an overview of the incidence that has been documented and to pinpoint the main risk factors for febrile neutropenia in NHL patients undergoing treatment. To find pertinent research published between 2010 and 2024, a literature search was carried out utilizing electronic databases such as PubMed, Google Scholar, ScienceDirect, and SpringerLink. The results show that the development of febrile neutropenia is significantly influenced by advanced age, comorbidities, poor performance status, advanced illness stage, bone marrow involvement, and intense chemotherapy regimens. Early identification of high-risk patients and suitable preventative treatments, such as granulocyte colony-stimulating factor prophylaxis, are critical to decrease complications and enhance treatment outcomes.